JP2015510496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510496A5 JP2015510496A5 JP2014548954A JP2014548954A JP2015510496A5 JP 2015510496 A5 JP2015510496 A5 JP 2015510496A5 JP 2014548954 A JP2014548954 A JP 2014548954A JP 2014548954 A JP2014548954 A JP 2014548954A JP 2015510496 A5 JP2015510496 A5 JP 2015510496A5
- Authority
- JP
- Japan
- Prior art keywords
- equal
- formula
- present
- pharmaceutically acceptable
- radioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 25
- 230000002285 radioactive effect Effects 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 12
- 238000002347 injection Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- -1 hydroxy carbonate compound Chemical class 0.000 claims 5
- 229910052751 metal Inorganic materials 0.000 claims 5
- 239000002184 metal Substances 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 229910052761 rare earth metal Inorganic materials 0.000 claims 4
- 150000002910 rare earth metals Chemical class 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 150000002739 metals Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- ALHBQZRUBQFZQV-UHFFFAOYSA-N tin;tetrahydrate Chemical compound O.O.O.O.[Sn] ALHBQZRUBQFZQV-UHFFFAOYSA-N 0.000 claims 2
- 150000000921 Gadolinium Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 108010046334 Urease Proteins 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 229910001938 gadolinium oxide Inorganic materials 0.000 claims 1
- 229940075613 gadolinium oxide Drugs 0.000 claims 1
- ILCLBMDYDXDUJO-UHFFFAOYSA-K gadolinium(3+);trihydroxide Chemical compound [OH-].[OH-].[OH-].[Gd+3] ILCLBMDYDXDUJO-UHFFFAOYSA-K 0.000 claims 1
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 235000014413 iron hydroxide Nutrition 0.000 claims 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578630P | 2011-12-21 | 2011-12-21 | |
| US61/578,630 | 2011-12-21 | ||
| US201261606734P | 2012-03-05 | 2012-03-05 | |
| US61/606,734 | 2012-03-05 | ||
| PCT/US2012/071256 WO2013096776A2 (en) | 2011-12-21 | 2012-12-21 | Radioactive compositions and methods for their therapeutic use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017047326A Division JP6356854B2 (ja) | 2011-12-21 | 2017-03-13 | 放射性構成物およびそれらの治療的使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510496A JP2015510496A (ja) | 2015-04-09 |
| JP2015510496A5 true JP2015510496A5 (enExample) | 2016-04-07 |
| JP6219841B2 JP6219841B2 (ja) | 2017-10-25 |
Family
ID=48669706
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548954A Active JP6219841B2 (ja) | 2011-12-21 | 2012-12-21 | 放射性構成物およびそれらの治療的使用方法 |
| JP2017047326A Active JP6356854B2 (ja) | 2011-12-21 | 2017-03-13 | 放射性構成物およびそれらの治療的使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017047326A Active JP6356854B2 (ja) | 2011-12-21 | 2017-03-13 | 放射性構成物およびそれらの治療的使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9687574B2 (enExample) |
| EP (1) | EP2793955B1 (enExample) |
| JP (2) | JP6219841B2 (enExample) |
| KR (2) | KR101973830B1 (enExample) |
| AU (1) | AU2012358364B2 (enExample) |
| CA (1) | CA2859971C (enExample) |
| ES (1) | ES2671622T3 (enExample) |
| WO (1) | WO2013096776A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101973830B1 (ko) * | 2011-12-21 | 2019-04-29 | 아이소테라퓨틱스 그룹 엘엘씨 | 방사성 조성물 및 그의 치료적 사용 방법 |
| CA2914496A1 (en) * | 2013-06-05 | 2014-12-11 | R-Nav, Llc | Treatment of immune, inflammatory and degenerative arthritides with tin-117m |
| SG11202105013YA (en) | 2018-12-14 | 2021-06-29 | Quirem Medical B V | Particle comprising lanthanide hydroxide |
| CA3143686A1 (en) * | 2019-06-18 | 2020-12-24 | Serene, Llc | A novel tin-117m colloid formulation with the ability to distinguish it from existing tin-117m colloid formulations |
| WO2021154746A1 (en) | 2020-01-28 | 2021-08-05 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4533541A (en) | 1983-08-25 | 1985-08-06 | The United States Of America As Represented By The United States Department Of Energy | Tin-117m-labeled stannic (Sn4+) chelates |
| JPH02501062A (ja) * | 1986-11-17 | 1990-04-12 | クラークソン ユニバーシティ | 希土類酸化物の均一なコロイド状粒子の合成方法 |
| US4906450A (en) * | 1987-03-26 | 1990-03-06 | Ephraim Lieberman | Treatment of arthritis, including rheumatoid arthritis, with the radionuclide, tin SN-121 |
| US5045289A (en) * | 1989-10-04 | 1991-09-03 | Research Corporation Technologies, Inc. | Formation of rare earth carbonates using supercritical carbon dioxide |
| US5320824A (en) * | 1989-10-12 | 1994-06-14 | Mallinckrodt Medical, Inc. | Radionuclide labelled particles useful for radiation synovectomy |
| US5061476A (en) * | 1989-12-27 | 1991-10-29 | The Dow Chemical Company | Radiolabeled colloid compositions and method for preparing same |
| US5137709A (en) * | 1991-02-15 | 1992-08-11 | The Dow Chemical Company | Layered mixed metal hydroxides for the stabilization of radioactive colloids |
| JP3122319B2 (ja) * | 1994-05-02 | 2001-01-09 | アソシエーティド ユニバーシティーズ，インコーポレイティド | 錫−１１７ｍ−含有放射性治療剤 |
| US6132642A (en) * | 1994-07-01 | 2000-10-17 | Sarnoff Corporation | Method of preparing small particle size phosphors |
| JP3734502B2 (ja) * | 1994-07-01 | 2006-01-11 | サーノフ コーポレイション | 小さな粒子サイズの蛍光体の調製方法 |
| US6231832B1 (en) | 1998-03-23 | 2001-05-15 | Brookhaven Science Associates | Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use |
| US6004532A (en) | 1998-06-08 | 1999-12-21 | Brookhaven Science Associates | Formulation for Tin-117m /diethylenetriaminepentaacetic acids |
| US7045166B2 (en) | 1998-08-27 | 2006-05-16 | Silver Barnard S | Sweetener compositions containing fractions of inulin |
| GB0020610D0 (en) | 2000-08-21 | 2000-10-11 | Dytech Corp Ltd | Uses of porous carriers |
| US7893223B2 (en) * | 2001-07-17 | 2011-02-22 | Bracco Imaging S.P.A. | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy |
| US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
| US7045116B2 (en) * | 2001-12-13 | 2006-05-16 | Dow Global Technologies Inc. | Treatment of osteomyelitis with radiopharmaceuticals |
| CA2509328A1 (en) * | 2002-12-10 | 2004-06-24 | University Of Miami | Radioablation of hemolymphopoietic cell populations |
| KR101106533B1 (ko) * | 2003-07-24 | 2012-01-20 | 브라코 이미징 에스.피.에이. | 안정한 방사성의약 조성물 및 제조 방법 |
| US20060014938A1 (en) * | 2004-07-14 | 2006-01-19 | Groman Ernest V | Stable aqueous colloidal lanthanide oxides |
| US20070259052A1 (en) * | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| CA2701537A1 (en) * | 2007-10-05 | 2009-04-09 | Isotherapeutics Group Llc | Compositions for treatment of tumors by direct administration of a radioisotope |
| US20100196268A1 (en) * | 2008-02-15 | 2010-08-05 | Isotherapeutics Group Llc | Compositions and methods for treatment of tumors by direct administration of a radioisotope |
| US20090191126A1 (en) * | 2007-11-27 | 2009-07-30 | The Regents Of The University Of California | Peptide and multivalent peptide conjugate for diagnosis and treatment of vascular plaques |
| US20110104052A1 (en) * | 2007-12-03 | 2011-05-05 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| EP2282781B1 (en) * | 2008-04-24 | 2018-09-05 | The Australian National University | Methods for radiolabelling synthetic polymers |
| US20120316633A1 (en) * | 2011-06-07 | 2012-12-13 | Boston Scientific Scimed, Inc. | Durable Stent Drug Eluting Coating |
| KR101973830B1 (ko) * | 2011-12-21 | 2019-04-29 | 아이소테라퓨틱스 그룹 엘엘씨 | 방사성 조성물 및 그의 치료적 사용 방법 |
| MY150861A (en) * | 2012-07-18 | 2014-03-06 | Univ Malaya | Neutron activated 153sm labelled microspheres |
-
2012
- 2012-12-21 KR KR1020147019820A patent/KR101973830B1/ko active Active
- 2012-12-21 CA CA2859971A patent/CA2859971C/en active Active
- 2012-12-21 JP JP2014548954A patent/JP6219841B2/ja active Active
- 2012-12-21 KR KR1020197011613A patent/KR102006599B1/ko active Active
- 2012-12-21 US US14/367,758 patent/US9687574B2/en active Active
- 2012-12-21 AU AU2012358364A patent/AU2012358364B2/en active Active
- 2012-12-21 ES ES12860525.0T patent/ES2671622T3/es active Active
- 2012-12-21 WO PCT/US2012/071256 patent/WO2013096776A2/en not_active Ceased
- 2012-12-21 EP EP12860525.0A patent/EP2793955B1/en active Active
-
2017
- 2017-03-13 JP JP2017047326A patent/JP6356854B2/ja active Active
- 2017-05-19 US US15/600,184 patent/US10583211B2/en active Active
-
2020
- 2020-01-27 US US16/773,398 patent/US10918746B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510496A5 (enExample) | ||
| FI3986890T3 (fi) | Bentsisoksatsolisulfonamidijohdannaisia | |
| HRP20221152T1 (hr) | Spojevi korisni u inhibiranju cdk7 | |
| CN111629755A (zh) | 联合放射疗法治疗癌症的粒子 | |
| GEP20053712B (en) | Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof | |
| IS6647A (is) | Kínasólínafleiður til að meðhöndla æxli | |
| WO2005061009A3 (en) | Microparticles for microarterial imaging and radiotherapy | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CN109549954B (zh) | 一种磷基材料制剂及其制备方法和应用 | |
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| CN107715122A (zh) | 医用磷酸钇[90y32po4]碳微球及其制备方法 | |
| JP2025516821A (ja) | 安定性の高い重金属除去組成物およびその用途、剤形、製造方法 | |
| FI3386546T3 (fi) | Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla | |
| RU2015152033A (ru) | Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт | |
| JP2021508338A (ja) | セスキテルペン誘導体の結晶形、およびその調製方法と用途 | |
| CN101780286A (zh) | 趋化因子受体cxcr4非肽类拮抗剂的放射性诊断与治疗药物 | |
| CN103301151A (zh) | 掺碘化银的生物活性玻璃及其的制备方法和应用 | |
| Dormehl et al. | Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model | |
| ES2628464T3 (es) | Complejos de galio, composiciones farmacéuticas y métodos de uso | |
| JP2006517195A5 (enExample) | ||
| JP2004509967A (ja) | 医学及び治療法の適用に使用するための金属錯体 | |
| JP7237366B2 (ja) | アスタチン溶液及びその製造方法 | |
| WO2013133873A3 (en) | Pharmaceutical compositions of sodium ion and calcium ion and methods for treating cancer, tumor and non-malignancy | |
| Chakraborty et al. | Evaluation of; 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy | |
| JP2020525477A5 (enExample) |